Clinical trials
Phase 3 Hemophilia B trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 4 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Recruiting | 6 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 7 |
| CSL Behring | 5 |
| Novo Nordisk A/S | 5 |
| Bioverativ Therapeutics Inc. | 3 |
| Baxalta now part of Shire | 2 |
| Genzyme, a Sanofi Company | 2 |
| Octapharma | 2 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 2 |
| Bioverativ, a Sanofi company | 1 |
| Cangene Corporation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia B | 32 |
| Hemophilia A | 13 |
| Hematologic Diseases | 4 |
| Hemorrhage | 4 |
| Blood Coagulation Disorders | 3 |
| Blood Coagulation Disorders, Inherited | 3 |
| Coagulation Protein Disorders | 3 |
| Genetic Diseases, Inborn | 3 |
| Genetic Diseases, X-Linked | 3 |
| Hemorrhagic Disorders | 3 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.